Related Experiment Video
Updated: Jan 5, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
17.0K
Germline testing for prostate cancer: community urology perspective
1Department of Urology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
The Canadian Journal of Urology
|October 21, 2019
Summary
Many community urology practices are incorporating hereditary cancer testing for prostate cancer patients. Key barriers include legal concerns, costs, and electronic health record (EHR) integration challenges.
Area of Science:
- Urology
- Oncology
- Medical Genetics
Background:
- Hereditary cancer testing is increasingly relevant for prostate cancer management.
- Understanding adoption patterns in community urology is crucial for wider implementation.
Purpose of the Study:
- To assess the current landscape of hereditary testing in community urology practices.
- To identify barriers hindering the integration of genetic testing and counseling for prostate cancer patients.
Main Methods:
- An eight-question online survey was distributed to 52 large community urology practices.
- The survey collected data on current testing patterns, genetic counseling utilization, and perceived obstacles.
Main Results:
- 63% of surveyed practices (32/52) reported offering hereditary testing to select patients.
- Primary barriers identified were: medical/legal liability fears (22%), reimbursement/patient cost concerns (20%), and EHR family history complexity (18%).
Conclusions:
- Community urology practices show a notable adoption rate for hereditary prostate cancer testing.
- Addressing practice concerns regarding liability, cost, and EHR integration is essential for broader uptake.
